Project cooperationUpdated on 15 December 2025
GeneCore: Advanced Transcriptomics (Single-cell/Spatial) & High-Throughput Screening Partner
Head of Core Facility at Institute of Biotechnology of the Czech Academy of Sciences
Vestec, Czech Republic
About
GeneCore Facility (Institute of Biotechnology of the Czech Academy of Sciences) is an academic core facility offering over 18 years of expertise in advanced transcriptomics technologies. We provide holistic, scalable solutions for bulk, single-cell, and spatial transcriptomics, ideal for exploring disease mechanisms (DISEASE-11) and integrating New Approach Methodologies (TOOL-03). Our capabilities include:
-
Bulk RNA-seq: Analysis of mRNA and small RNA (biomarkers) in standard and challenging samples (low input, FFPE).
-
High-Throughput NAMs: Scalable in-vitro screening solutions without RNA isolation, enabling cost-effective high-throughput drug/toxicity testing.
-
Single-Cell Experts: We cover the full spectrum from highly sensitive targeted plate-based approaches (SmartSeq3xpress) and industry-standard 10x Genomics, to high-throughput complementary techniques (Parse Bioscience, Scale Biosciences).
-
Spatial & Sequencing: Sequencing-based spatial transcriptomics and access to the latest instruments (Illumina, Element Biosciences).
We offer a complete service package including experimental design, hands-on protocols, established QC workflows, and interactive data visualization. We are looking to join a consortium as a partner to provide exploratory or explanatory in-depth transcriptomic analysis at any scale.
Topic
- DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-11: Understanding of sex and/or gender-specific mechanisms of cardiovascular diseases: determinants, risk factors and pathways
- DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-03: Integrating New Approach Methodologies (NAMs) to advance biomedical research and regulatory testing
Type
- Partner seeks Consortium/Coordinator
Attached files
Organisation
Similar opportunities
Project cooperation
- Partner seeks Consortium/Coordinator
- DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-15: Scaling up innovation in cardiovascular health
- DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-03: Advancing research on the prevention, diagnosis, and management of post-infection long-term conditions
- DESTINATION 1: HORIZON-HLTH-2026-01-STAYHLTH-02: Behavioural interventions as primary prevention for Non-Communicable Diseases (NCDs) among young people
- DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-11: Understanding of sex and/or gender-specific mechanisms of cardiovascular diseases: determinants, risk factors and pathways
- DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-09: Multisectoral approach to tackle chronic non-communicable diseases: implementation research maximising collaboration and coordination with sectors and in settings beyond the healthcare system (GACD)
Vita Rovite
Senior Researcher at Latvian Biomedical Research and Study centre
Riga, Latvia
Project cooperation
LNP delivery with barcoded mRNA
- Partner seeks Consortium/Coordinator
- DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-07: Establishing a European network of Centres of Excellence (CoEs) for Advanced Therapies Medicinal Products (ATMPs)
Filip Van Nieuwerburgh
Professor at Ghent University
Ghent, Belgium
Project cooperation
Integrating RNA-seq and Mechanistically Interpretable Machine Learning for Toxicity Prediction
- Partner seeks Consortium/Coordinator
- DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-03: Integrating New Approach Methodologies (NAMs) to advance biomedical research and regulatory testing
- DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-06: Support to European Research Area (ERA) action on accelerating New Approach Methodologies (NAMs) to advance biomedical research and testing of medicinal products and medical devices
Filip Van Nieuwerburgh
Professor at Ghent University
Ghent, Belgium